Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B‐cell lymphomas

Takezaki et al. analyzed the outcome of 57 patients with indolent lymphomas treated with Bendamustine plus Rituximab (BR) according to the number of cycles received, showing that patients who discontinued BR after four cycles had similar outcomes compared to patients who received five or six cycles....

Full description

Saved in:
Bibliographic Details
Published in:Hematological oncology 2023-08, Vol.41 (3), p.571-573
Main Authors: Autore, Francesco, Fresa, Alberto, Innocenti, Idanna, Principe, Maria Ilaria Del, Maglione, Raffaele, Stefanizzi, Caterina, Pelliccia, Sabrina, Romeo, Azzurra, Cimino, Giuseppe, Papa, Elena, Padua, Laura De, Andriani, Alessandro, Mengarelli, Andrea, Tafuri, Agostino, Ditto, Concetta, Mauro, Francesca Romana, Del Poeta, Giovanni, Laurenti, Luca
Format: Article
Language:English
Subjects:
B-cell lymphoma
bendamustine
Chronic lymphocytic leukemia
Immunotherapy
Leukemia
Lymphoma
Monoclonal antibodies
Patients
Rituximab
shortening chemotherapy
Targeted cancer therapy
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Takezaki et al. analyzed the outcome of 57 patients with indolent lymphomas treated with Bendamustine plus Rituximab (BR) according to the number of cycles received, showing that patients who discontinued BR after four cycles had similar outcomes compared to patients who received five or six cycles. Considering the similarities but also the differences between indolent lymphomas and chronic lymphocytic leukemia (CLL), we enriched the results obtained with a cohort of CLL patients treated with BR starting from the experience of the Lazio region group on CLL. Out of 115 patients, 97 (84%) received 4–6 cycles of BR, while 18 (16%) received 1–3 cycles. The outcome of the group of patients who received at least 4 cycles was superior in terms of response rate (ORR 96% vs. ORR 83%, p = 0.041; CR 58% vs. CR 28%, p = 0.052 respectively) and PFS [median PFS 52.6 (40.3–64.9) versus 26.2 (19.3–33.0) months, p 
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2989